Spots Global Cancer Trial Database for carcinoma, squamous cell of head and neck
Every month we try and update this database with for carcinoma, squamous cell of head and neck cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Concurrent Chemoradiotherapy(CRT) in Locally Advanced(LA) SCCHN vs Cetuximab With Radiotherapy (RT) After Neoadjuvant Chemotherapy | NCT02753140 | Carcinoma, Squa... | Cetuximab radiation Docetaxel Cisplatin | 18 Years - | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | |
| Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC | NCT03291002 | Melanoma (Skin) Squamous Cell C... Carcinoma, Squa... Carcinoma, Aden... | CV8102 CV8102 + anti-P... | 18 Years - | CureVac | |
| Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma | NCT02296684 | Cancer of Head ... Head and Neck C... Neoplasms, Head... Carcinoma, Squa... Squamous Cell C... Squamous Cell C... | MK-3475 (neoadj... Surgery Intensity modul... Image-guided ra... Cisplatin MK-3475 (adjuva... Peripheral bloo... | 18 Years - | Washington University School of Medicine | |
| PD 0332991 and Cetuximab in Patients With Incurable SCCHN | NCT02101034 | Carcinoma, Squa... | Cetuximab PD 0332991 | 18 Years - | Washington University School of Medicine | |
| Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) | NCT02277197 | Carcinoma, Squa... Squamous Cell C... Squamous Cell C... | Ficlatuzumab Cetuximab | 18 Years - | University of Pittsburgh | |
| Copanlisib in Association With Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas Harboring a PI3KCA Mutation/Amplification and/or a PTEN Loss | NCT02822482 | Carcinoma, Squa... | Copanlisib Cetuximab | 18 Years - | UNICANCER | |
| Biomarker-based Study in R/M SCCHN | NCT03088059 | Carcinoma, Squa... | Afatinib Palbociclib standard of car... IPH2201 Durvalumab Niraparib INCAGN01876 | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | NCT01836029 | Carcinoma, Squa... | VTX-2337 Carboplatin Cisplatin 5-fluorouracil Placebo | 18 Years - | Celgene | |
| Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma | NCT02277184 | Carcinoma, Squa... | Ficlatuzumab Cisplatin Intensity Modul... | 18 Years - | University of Pittsburgh | |
| A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 | NCT06003231 | Carcinoma, Squa... Carcinoma, Non-... Ovarian Neoplas... Endometrial Neo... | disitamab vedot... | 18 Years - | Seagen Inc. | |
| Concurrent Chemoradiotherapy(CRT) in Locally Advanced(LA) SCCHN vs Cetuximab With Radiotherapy (RT) After Neoadjuvant Chemotherapy | NCT02753140 | Carcinoma, Squa... | Cetuximab radiation Docetaxel Cisplatin | 18 Years - | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | |
| Sym004 in SCCHN Patients Failing Anti-EGFR Based Therapy | NCT01417936 | Carcinoma, Squa... | Sym004 | 18 Years - | Symphogen A/S | |
| A Post Marketing Surveillance Study of Cetuximab in Patients With Squamous Cell Carcinoma of Head and Neck (SCCHN) | NCT01080066 | Carcinoma, Squa... | No Intervention | 18 Years - | Merck KGaA, Darmstadt, Germany | |
| A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors | NCT02952989 | Carcinoma, Non-... Carcinoma, Rena... Breast Neoplasm... Urinary Bladder... Carcinoma, Squa... Colorectal Neop... Gastric Adenoca... Gastroesophagea... | SGN-2FF pembrolizumab | 18 Years - | Seagen Inc. | |
| Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer | NCT03715946 | Carcinoma, Squa... Oropharynx Squa... | Nivolumab Injec... Radiotherapy (R... | 18 Years - | University of Pittsburgh | |
| A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors | NCT05551117 | Castration-Resi... Androgen-Indepe... Androgen-Insens... Androgen-Resist... Hormone Refract... Anal Cancer Anal Neoplasm Carcinoma, Squa... Head and Neck S... Laryngeal Squam... Oral Squamous C... Malignant Melan... Melanoma Non-small Cell ... Non-small Cell ... Small-cell Lung... Small Cell Carc... | vobramitamab du... vobramitamab du... vobramitamab du... | 18 Years - | MacroGenics | |
| NC-6004 With 5-FU and Cetuximab for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | NCT03109158 | Carcinoma, Squa... | NC-6004 Cetuximab 5-FU | 18 Years - | NanoCarrier Co., Ltd. | |
| Safety and Efficacy of Radiation/Cetuximab Plus EGFR Antisense DNA for Head and Neck Squamous Cell Carcinoma | NCT00903461 | Carcinoma, Squa... Squamous Cell C... Squamous Cell C... | EGFR Antisense ... | 18 Years - | University of Pittsburgh | |
| Safety,Tolerability,and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell Carcinoma | NCT03799744 | Head and Neck N... Carcinoma, Squa... Metastasis Recurrence | VCN-01 Durvalumab | 18 Years - | Institut Català d'Oncologia | |
| Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer | NCT03715946 | Carcinoma, Squa... Oropharynx Squa... | Nivolumab Injec... Radiotherapy (R... | 18 Years - | University of Pittsburgh | |
| Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC | NCT02585973 | Carcinoma, Squa... | AZD1775 Cisplatin Intensity Modul... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Ketogenic Diet Phase 1 for Head & Neck Cancer | NCT01975766 | Head and Neck N... | Ketogenic diet External beam r... | 18 Years - | University of Iowa | |
| A Study to Evaluate the Safety and Efficacy of Amphinex Induced PCI of Bleomycin for Recurrent Head and Neck Cancer. | NCT01606566 | Recurrent Head ... Carcinoma, Squa... | Amphinex induce... | 18 Years - | PCI Biotech AS | |
| A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors | NCT02952989 | Carcinoma, Non-... Carcinoma, Rena... Breast Neoplasm... Urinary Bladder... Carcinoma, Squa... Colorectal Neop... Gastric Adenoca... Gastroesophagea... | SGN-2FF pembrolizumab | 18 Years - | Seagen Inc. | |
| Bevacizumab/Ph 2 for Locally Advanced Head and Neck Cancer | NCT01588431 | Carcinoma, Squa... | Docetaxel, Cisp... | 18 Years - | The University of Texas Health Science Center at San Antonio | |
| A Randomized Phase II Study on the Optimization of Immunotherapy in Squamous Carcinoma of the Head and Neck | NCT03620123 | Recurrent or Me... Carcinoma, Squa... | Nivolumab and I... Docetaxel | 18 Years - | AIO-Studien-gGmbH | |
| Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors | NCT03485209 | Colorectal Neop... Carcinoma, Non-... Exocrine Pancre... Carcinoma, Squa... | tisotumab vedot... pembrolizumab carboplatin cisplatin | 18 Years - | Seagen Inc. | |
| Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | NCT01836029 | Carcinoma, Squa... | VTX-2337 Carboplatin Cisplatin 5-fluorouracil Placebo | 18 Years - | Celgene | |
| Sym004 in SCCHN Patients Failing Anti-EGFR Based Therapy | NCT01417936 | Carcinoma, Squa... | Sym004 | 18 Years - | Symphogen A/S | |
| A Prospective Study of Prophylactic Gastrostomy in Head and Neck Cancer Patients Undergoing Chemoradiotherapy | NCT01876693 | Carcinoma, Squa... | prophylactic pe... | 18 Years - | Mahidol University | |
| Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck | NCT02289209 | Recurrent Head ... Carcinoma, Squa... | Reirradiation MK-3475 | 18 Years - | University of Pittsburgh | |
| Treatment of Advanced Head and Neck Cancer | NCT00982696 | Carcinoma, Squa... | Opioid Growth F... | 18 Years - | Milton S. Hershey Medical Center | |
| Smoking Tobacco Cessation Integrated Program of Patients Treated for the Head and the Neck Cancer | NCT03788785 | Carcinoma, Squa... Tobacco Use Dis... | Experimental ar... Control arm | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| Concurrent Chemoradiotherapy(CRT) in Locally Advanced(LA) SCCHN vs Cetuximab With Radiotherapy (RT) After Neoadjuvant Chemotherapy | NCT02753140 | Carcinoma, Squa... | Cetuximab radiation Docetaxel Cisplatin | 18 Years - | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | |
| Bioimmunoradiotherapy (Cetuximab/RT/Avelumab) | NCT02938273 | Carcinoma, Squa... | avelumab radiotherapy cetuximab | 18 Years - | The Netherlands Cancer Institute | |
| A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab | NCT01307267 | Lymphoma, Non-H... Lymphoma, Folli... Lymphoma, Large... Carcinoma, Non-... Carcinoma, Rena... Carcinoma, Squa... Malignant Melan... | PF-05082566 rituximab PF-05082566 | 18 Years - | Pfizer | |
| A Phase 1 Study in Participants With Advanced Cancer | NCT01115790 | Advanced Cancer Squamous Cell C... Carcinoma, Squa... Lung Squamous C... Anal Squamous C... Carcinoma, Non-... | Prexasertib | 18 Years - | Eli Lilly and Company | |
| Treatment of Advanced Head and Neck Cancer | NCT00982696 | Carcinoma, Squa... | Opioid Growth F... | 18 Years - | Milton S. Hershey Medical Center | |
| Research of Biomarkers of Activity and Efficacy of BIBW2992 in Untreated Non-metastatic HNSCC Patients | NCT01415674 | Carcinoma, Squa... | Afatinib | 18 Years - | UNICANCER | |
| A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors | NCT05551117 | Castration-Resi... Androgen-Indepe... Androgen-Insens... Androgen-Resist... Hormone Refract... Anal Cancer Anal Neoplasm Carcinoma, Squa... Head and Neck S... Laryngeal Squam... Oral Squamous C... Malignant Melan... Melanoma Non-small Cell ... Non-small Cell ... Small-cell Lung... Small Cell Carc... | vobramitamab du... vobramitamab du... vobramitamab du... | 18 Years - | MacroGenics | |
| A Randomized Phase II Study on the Optimization of Immunotherapy in Squamous Carcinoma of the Head and Neck | NCT03620123 | Recurrent or Me... Carcinoma, Squa... | Nivolumab and I... Docetaxel | 18 Years - | AIO-Studien-gGmbH | |
| Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck | NCT02113878 | Carcinoma, Squa... HPV Positive Or... Hypopharyngeal ... Early Invasive ... Carcinoma of La... Cancer of Nasop... | BKM120 Cisplatin Intensity-modul... | 18 Years - | Dana-Farber Cancer Institute | |
| CetuGEX™ in Comparison to Cetuximab for the Treatment of Patients With Head and Neck Cancer | NCT02052960 | Carcinoma, Squa... | CetuGEX™ Cetuximab Chemotherapy | 18 Years - | Glycotope GmbH | |
| Safety and Efficacy of Radiation/Cetuximab Plus EGFR Antisense DNA for Head and Neck Squamous Cell Carcinoma | NCT00903461 | Carcinoma, Squa... Squamous Cell C... Squamous Cell C... | EGFR Antisense ... | 18 Years - | University of Pittsburgh | |
| Safety,Tolerability,and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell Carcinoma | NCT03799744 | Head and Neck N... Carcinoma, Squa... Metastasis Recurrence | VCN-01 Durvalumab | 18 Years - | Institut Català d'Oncologia | |
| Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma | NCT02277184 | Carcinoma, Squa... | Ficlatuzumab Cisplatin Intensity Modul... | 18 Years - | University of Pittsburgh | |
| Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer | NCT03715946 | Carcinoma, Squa... Oropharynx Squa... | Nivolumab Injec... Radiotherapy (R... | 18 Years - | University of Pittsburgh | |
| Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | NCT01836029 | Carcinoma, Squa... | VTX-2337 Carboplatin Cisplatin 5-fluorouracil Placebo | 18 Years - | Celgene | |
| A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer | NCT03735290 | Carcinoma, Squa... Gastric Adenoca... Gastroesophagea... Non-small Cell ... | ilixadencel Pembrolizumab | 18 Years - | Mendus | |
| PD 0332991 and Cetuximab in Patients With Incurable SCCHN | NCT02101034 | Carcinoma, Squa... | Cetuximab PD 0332991 | 18 Years - | Washington University School of Medicine |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
